- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Lobe Sciences Ltd (2): Lobe Sciences cheers U.S. order for novel treatments | 4 | Stockwatch | ||
| 23.04. | Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders | 189 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing... ► Artikel lesen | |
| 21.04. | Lobe Sciences Ltd (2): Lobe Sciences hires Massive Intelligence for IR | 1 | Stockwatch | ||
| 21.04. | Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services | 257 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 20.04. | Lobe Sciences Ltd (2): Lobe Sciences closes $950,000 private placement | 2 | Stockwatch | ||
| 20.04. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update | 232 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.04. | Lobe Sciences launches non-brokered private placement of 14.62M shares at $0.065 | 2 | Seeking Alpha | ||
| 11.04. | Lobe Sciences Ltd (2): Lobe Sciences arranges $950,000 private placement | 2 | Stockwatch | ||
| 11.04. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 610 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. meldet verbesserte Finanzlage und gibt strategisches Update bekannt | 355 | IR-WORLD | - Verbindlichkeiten um 81 % reduziert, von 2,35 Mio. $ auf 0,44 Mio. $
- Barmittel um mehr als das 24-Fache gestiegen, von 0,24 Mio. $ auf 5,99 Mio. $
... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update | 264 | ACCESS Newswire | Liabilities reduced 81%, from $2.35M to $0.44MCash increased more than 24x, from $0.24M to $5.99MNet working capital improved by $6.1M, from ($2.01M) to $4.05MOutstanding warrants reduced by ~70%, from... ► Artikel lesen | |
| 09.03. | Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao | 1 | Seeking Alpha | ||
| 09.03. | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 412 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen | |
| 05.03. | Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences | 212 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British... ► Artikel lesen | |
| 03.02. | Lobe Sciences Ltd (2): Lobe Sciences' Nov. 30 cash at $5.99-million | 1 | Stockwatch | ||
| 03.02. | Lobe Sciences Ltd.: Lobe Sciences Reports First Quarter 2026 Results and Highlights | 371 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases... ► Artikel lesen | |
| 13.01. | Lobe Sciences Ltd (2): Lobe Sciences appoints Karakochuk as director | 1 | Stockwatch | ||
| 13.01. | Lobe Sciences Ltd.: Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors | 362 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 09.01. | Lobe Sciences Ltd (2): Lobe Sciences ends FY 2025 with cash of $5.85-million | 1 | Stockwatch | ||
| 08.01. | Lobe Sciences Ltd.: Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | 289 | ACCESS Newswire | Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,310 | +4,38 % | BioNxt setzt auf fortschrittliche Drug-Delivery-Strategie und psychedelische Wirkstoffbibliothek im aufstrebenden Therapeutika-Markt bei wachsender globaler Dynamik | VANCOUVER, BC / ACCESS Newswire /
28. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| ATAIBECKLEY | 3,500 | -1,69 % | Psychedelika im Aufwind - AtaiBeckley und Emyria im Fokus | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | CSE Bulletin: Suspension - SOL Global Investments Corp. (SOL) | Le 7 avril/April 2026
Effective immediately, SOL Global Investments Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,041 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Execution of Business Combination Agreement with Nutravisor | Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| CYBIN | 4,290 | -5,09 % | Helus Pharma appoints Ken Kramer as Senior VP, Medical Affairs | ||
| REVIVE THERAPEUTICS | 0,010 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases | Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11,... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics treibt die Erweiterung der pharmazeutischen Produktion | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) treibt die Erweiterung der pharmazeutischen Produktion - durch Modernisierungen am Standort Burlington... ► Artikel lesen | |
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,960 | +1,67 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| AVALYN PHARMA | 29,015 | 0,00 % | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| ALUMIS | 24,690 | +7,86 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 88,20 | +0,06 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ERASCA | 10,640 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,240 | 0,00 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| TANGO THERAPEUTICS | 21,530 | -2,40 % | Stifel raises Tango Therapeutics stock price target on drug combo potential |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -14,75 % bei einem Aktienkurs von 0,052 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.